Jury Sides With Endo And Impax On 2014 Opana Antitrust Suit
Opana ER Purchasers Claimed $102m Endo Payment ‘Effectively Guaranteed’
Executive Summary
Endo and Impax have received a favorable jury verdict after a 2010 patent-litigation settlement between the pair over Endo’s Opana ER was alleged to have been “an anticompetitive scheme that restrained competition,”
You may also be interested in...
FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws
In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.